Skip to main content
. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776

Table 1.

Demographics at baseline.

Population characteristics Overall cohort gBRCA-wt gBRCA-mut
35 (100.0%) N=27 (77.1%) N=8 (22.9%)
Age (years)
Mean (SD) 60 ( ± 15) 62 ( ± 15) 54 ( ± 12)
Germline BRCA1/2 Mutational Status
BRCA-mutant 8 (22.9%) 0 (0.0%) 8 (100%)
BRCA-wild type 27 (77.1%) 27 (100.0%) 0 (0.0%)
Breast Cancer Subtype
TNBC 33 (94.3%) 27 (100.0%) 6 (75.0%)
HR+/HER2-neg. 2 (5.7%) 0 (0.0%) 2 (25.0%)
HER2+ 0 (0%) 0 (0.0%) 0 (0.0%)
Primary Tumor Dimension (mm)
Median (min - max) 39 (18 - 80) 37 (18 -75) 50 (20 - 80)
TNM Stage
I-IIA 0 (0.0%) 0 (0.0%) 0 (0.0%)
IIB-IIIC 35 (100.0%) 27 (100.0%) 8 (100.0%)
IV 0 (0.0%) 0 (0.0%) 0 (0.0%)
SUVmax
Median (min - max) 9.3 (1.9 - 31.0) 8.7 (1.9 - 31.9) 11.7 (3.8 - 21.9)
Ki67%
Median (min - max) 50% (10% - 90%) 50% (15% – 90%) 63% (10% - 80%)
TILs
Median (min - max) 40 (10 - 90) 40 (10 - 90) 90 (10 - 90)
PD-L1
Negative (<1%) 9 (29.0%) 8 (33.3%) 1 (14.3%)
Positive (≥1%) 22 (71.0%) 16 (66.7%) 6 (85.7%)

Means with standard deviation are reported when the variable distribution was normal according to a Shapiro-Wilk test for normality, otherwise median values with minimum-maximum range are reported; SD, standard deviation; TILs, tumor-infiltrating lymphocytes; SUV, standard uptake volume; PD-L1, PD-L1 in tumor-infiltrating inflammatory cells; gBRCA-wt, germinal BRCA1/2-wild type triple negative tumors; gBRCA-mut, germinal BRCA1/2-mutant tumors.